Düsseldorf, Germany (PRWEB) June 13, 2013
University Hospital Düsseldorf and the University Cancer Center Düsseldorf announced today the launch of a new medical education training portal that helps physicians to diagnose patients with myelodysplastic syndromes. This interactive online program is available to haematologists and qualified HCPs and offers over 50 patient cases, as well as expert lectures from the world’s leading authorities on myelodysplastic syndromes, the most frequent malignant stem cell disorder in the elderly.
Myelodysplastic syndromes (MDS) are a group of conditions that occur when the blood-forming cells in the bone marrow are damaged, leading to ineffective blood production and abnormally low blood counts. Approximately 25% of patients with MDS will progress to acute myeloid leukemia (AML), a cancer of the white blood cells. People with MDS typically have low blood cell counts, which means they have very low levels of red blood cells (RBCs) (anemia), white blood cells (WBCs) (neutropenia), and/or platelets (thrombocytopenia). The incidence of MDS is thought to be between 3.5 to 12.6 per 100,000 population per year, with higher rates for people over 70 years of age.
“MDS can be difficult to diagnose because there are many different types of MDS and the signs and symptoms of MDS, if they are present, are non-specific,” says Dr. Ulrich Germing, the Vice Head of the Department of Haemotology, Oncology and Clinical Immunology at University Hospital Düsseldorf. “In addition, the list of differential diagnoses is long”. Professor Germing, who has co-authored more than 220 articles in international peer-reviewed journals, noted that “there is a clear need to educate physicians about tests that can be used to diagnose and classify MDS, as well as to predict outcomes and select appropriate treatment options.”
Copyright©2012 Vocus, Inc.
All rights reserved